The test, called CoVarScan, was developed by Jeffrey SoRelle, MD, a pathologist at UT Southwestern, and colleagues, according to a June 30 news release. The typical process for identifying which SARS-CoV-2 variant a person has relies on whole genome sequencing — a timely and expensive process that essentially reads the virus’ entire RNA sequence.
Instead, the ConVarScan looks at eight regions of the SARS-COV-2 virus to detect small mutations. In these specific regions, each variant looks different. The team evaluated how well the test works by running it on more than 4,000 COVID-19-positive swab samples collected at UT Southwestern from April 2021 to February 2022, and validated the results with whole genome sequencing. They found CoVarScan had very similar accuracy to the gold standard, according to findings published in Clinical Chemistry.
Eventually, researchers anticipate the test can be used to better match treatments based on which variants a patient has, as well as help determine which variants are circulating in a community and if a new one is emerging.
Dr. SoRelle plans to develop CoVarScan as a commercial test and has a pending patent application.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.